RELATED STUDY

Camphene, a Plant-Derived Monoterpene, Reduces Plasma Cholesterol and Triglycerides in Hyperlipidemic Rats Independently of HMG-CoA Reductase Activity.

Key Findings:  Administration of camphene at a dose of 30 µg/gr of body weight in hyperlipidemic rats resulted in a 54.5% reduction of total cholesterol, 54% of Low Density Lipoprotein (LDL)-cholesterol and 34.5% of triglycerides. Given the critical role that the control of hyperlipidemia plays in cardiovascular disease, the results of our study provide insights into the use of camphene as an alternative lipid lowering agent and merits further evaluation.

Type of Study:  Animal Study

Study Result:  Positive

Study Location(s):  Australia, Greece, United States

Year of Pub:  2011


Cannabinoids Studied: 

Terpenes Studied:  ß-Caryophyllene, Camphene, Linalool, Myrcene, Pinene

Dosage: Camphene (30 µg/gr)

Route of Administration:  Injection



Link to study